Icon

Nerlynx - (40 mg; Tablets)

Neratinib Maleate Puma Biotech
40 mg; Tablets
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy
Yes
*** *********** ******* ** **** **, ****. ** ******** **, ****, **** ******* *** ’*** ****** *** ***. *********, **** *** *** *********** ** ******, *** ********** ** *** ’*** ****** **** ** ******** **, ****, *** *** ****** **** **** ** ********* ***********.
Nerlynx Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10
****** ******* **** *** **** *** ******* **** *** **** *** **** *** **** *** **** *** **** ***
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** / ********* *** **, **** ******* ********* ******** ******* *** **** *** *** ****
  1. *** **, **** : * **** ** *** ***** *** ***** ** * *** *******.
  2. *** **, **** : ****** ******** **** ********* *** **** ** ****** *** * ******.
  3. *** **, **** : **** ********* ****** **** ****** '***.
  4. *** **, **** : **** ********* ********** **** ******. ** ****** ** ** * **********.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.